Relationship between depressive symptoms and long-term mortality in patients with heart failure - 16/08/11
, Maragatha Kuchibhatla, PhD c, Greg L. Clary, MD d, Michael S. Cuffe, MD, FACC a, Eric J. Christopher, MD a, b, Jude D. Alexander, MD e, Robert M. Califf, MD, FACC a, Ranga R. Krishnan, MD b, Christopher M. O'Connor, MD, FACC aRésumé |
Background |
Depression is prevalent in patients with heart failure (HF) and is associated with short-term poor prognosis. However, the long-term effect of depression and the use of self-administered depression evaluation on HF prognosis remained unknown. The study sought to assess the association of depressive symptoms and long-term mortality of patients with HF and to explore the prognostic predictability of the Beck Depression Inventory (BDI) scale for patients with HF.
Methods |
Hospitalized patients with HF between March 1997 and June 2003 were recruited. All participants were given the self-administered BDI scale for depression assessment during the index admission. They were then followed for 6 months for the collection of vital status, and annually thereafter.
Results |
Total study population comprises 1006 patients. The mean BDI score was 8.3 ± 7.1. The average days of follow-up were 971 ± 730 and the vital status was obtained from all participants. During this period, 42.6% of the participants died. Depression (defined by BDI score ≥10) was significantly and independently associated with reduced survival (adjusted hazard ratio 1.36, 95% CI 1.09-1.70, P < .001). Patients whose BDI scores were 5 to 9, 10 to 18, and ≥19 were 21%, 53%, and 83% more likely to die, respectively, than patients whose BDI score was <5 (P < .001).
Conclusions |
Self-rated depression by BDI is independently linked with higher long-term mortality in patients with HF. Significant dose effect of depressive symptoms on higher mortality is noted.
Le texte complet de cet article est disponible en PDF.Plan
| The study was supported in part by National Institutes of Mental Health grants R01MH51191 and R01MH63211-Minority Supplement Award (WJ), and the APIRE/Merck & Co. Early Academic Career Research Award, 2004 (WJ). |
Vol 154 - N° 1
P. 102-108 - juillet 2007 Retour au numéro
Article précédent
- Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND)
- Michael Böhm, Magnus Baumhäkel, Jeffrey L. Probstfield, Roland Schmieder, Salim Yusuf, Feng Zhao, Teo Koon, On Behalf of the ONTARGET/TRANSCEND ED-Investigators
- Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: Data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial
- Daniela Dobre, Dirk J. van Veldhuisen, Giacomo Mordenti, Marius Vintila, Flora M. Haaijer-Ruskamp, Andrew J.S. Coats, Philip A. Poole-Wilson, Marcus D. Flather, on behalf of the SENIORS Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?